作者：金杜律师事务所 King & Wood Mallesons

上海医药集团股份有限公司（简称“上海医药”）以及Primavera Capital Fund II L.P.（简称“春华”）在金杜律师事务所专业团队的协助下，通过协议收购澳大利亚证券交易所上市公司Vitaco Holdings Ltd（简称“Vitaco”）的100%股份。上海医药和春华将以每股2.25澳元收购Vitaco，交易对目标公司的估值为3.137亿澳元。

King & Wood Mallesons (KWM) is acting for Shanghai Pharmaceuticals Holding Co., Ltd (“Shanghai Pharma”) and Primavera Capital Fund II L.P. (“Primavera”) on their joint acquisition of 100% of ASX-listed Vitaco Holdings Ltd (“Vitaco”) by way of scheme of arrangement. Shanghai Pharma and Primavera are offering Vitaco shareholders A$2.25 per share (less any dividend paid), valuing Vitaco at A$313.7 million.

交易各方已签署《收购安排实施协议》，该消息于2016年8月4日已向市场公布。该协议目前尚需满足一系列惯例的交割条件，其中包括股东大会、法院以及相关监管机构的批准。Vitaco股东预计将于2016年11月就该协议进行投票表决，协议有望于今年12月生效。

The parties have entered into a scheme implementation deed which was released to the market earlier today (4 August 2016). The scheme is subject to a number of customary conditions including shareholder and court approval and relevant regulatory approvals and is expected to be voted on by Vitaco shareholders in November 2016 with implementation of the scheme expected to occur in December 2016.

Vitaco是一家在澳大利亚及新西兰经营维生素及保健品、体育营养品以及健康食品的领先企业，开发、生产及销售一系列国际一流品牌的营养、保健及健康产品。

Vitaco is a leading vitamins and supplements, sports nutrition, and health foods business in Australia and New Zealand that develops, manufactures and markets world-class nutrition products under market-leading brands across the broader nutrition, health and wellness category.

上海医药是一家总部在上海，并已在上海和香港两地上市的领先医药集团，其主要业务覆盖医药研发、制造、分销及零售。春华资本是一家立足于亚洲的领先投资公司，能够将其在全球资本市场的丰富经验、深入的行业知识以及与亚洲乃至全球的决策者和商业领袖的强大网络相结合。

Shanghai Pharma is a leading pharmaceutical group headquartered in Shanghai.  It is listed on both the Shanghai Stock Exchange and the Hong Kong Exchange.  Shanghai Pharma’s principal business covers pharmaceutical research and development, manufacturing, distribution and retailing.  Primavera Capital is a leading Asia-based investment firm that combines global capital market experience, deep industry knowledge, and a strong network of relationships with policy-makers as well as leading business leaders and entrepreneurs in Asia and globally.

负责该项目的金杜法律团队由北京合伙人徐萍律师、葛杰律师和悉尼合伙人Shannon Finch主导，律师团队包括Clifford Sandler、Tom Harrison、黄云竹和Kenny Chen。该项目同时还得到中国、香港及澳大利亚办公室多位合伙人及律师的大力支持。

The KWM team was led by partners Xu Ping and Jonathan Grant (both based in Beijing) and Shannon Finch (based in Sydney), supported by lead Senior Associate Clifford Sandler together with Tom Harrison, Huang Yunzhu and Kenny Chen and a number of other partners and associates across our China, Hong Kong and Australian offices.

徐萍律师表示，“该项目再次体现了金杜帮助中国企业成功完成跨境并购交易、实施全球化战略中的强大专业实力。金杜拥有中国及澳大利亚具有市场领先地位的优秀团队，凭借深厚的专业知识和丰富经验，帮助客户就交易涉及的复杂法律问题找到解决方案，满足中国及澳大利亚的不同监管要求，积极应对两国不同的商业实践，最终达成交易。”

Xu Ping said, “This deal once again proves KWM’s capabilities to guide Chinese clients through the legal maze in making overseas investments and implementing their globalisation strategy. With strong professional expertise and practical experiences in both PRC and Australia, our team successfully assisted our clients in resolving complex legal issues, meeting regulatory requirements in both China and Australia, and working out the different market practices of the two countries.”

葛杰表示，“金杜很荣幸在这一令人振奋的交易中协助上海医药和春华资本。为成功与Vitaco达成协议并为Vitaco及其股东提供资金及执行的确定性，金杜在中国、香港及澳大利亚的全球法律团队为解决该交易中涉及的众多复杂跨境法律、监管及交易管理问题提供了专业熟练的法律服务。”

Jonathan Grant said, “KWM is honoured to have acted for Shanghai Pharma and Primavera on this exciting transaction.  The transaction involved complex cross-border legal, regulatory and transaction management issues which the KWM global team in China, Hong Kong and Australia was able to expertly manage in order to successfully negotiate a deal with Vitaco that addressed those complex issues while delivering funding and execution certainty for Vitaco and its shareholders.”

Shannon Finch表示，“为了适应此次跨境交易的内在要求并支持交易的确定性，此次交易还融入了许多创新元素。我们的专家团队提出了许多具有创造性以及商业性的想法，从而满足交易各方的诉求。”

Shannon Finch commented,  “The transaction also involved a number of innovative elements to accommodate the cross border nature of the transaction and to support deal certainty.  The advisory teams brought real creativity and commerciality to the table to meet all parties’ needs.”